FXYD1 was identified as a hub gene in recurrent miscarriage and involved in decidualization via regulating Na/K-ATPase activity
- PMID: 39730944
- PMCID: PMC11871252
- DOI: 10.1007/s10815-024-03363-8
FXYD1 was identified as a hub gene in recurrent miscarriage and involved in decidualization via regulating Na/K-ATPase activity
Abstract
Purpose: Recurrent miscarriage (RM) is a distressing and complicated adverse pregnancy outcome. It is commonly recognized that insufficient decidualization could result in RM, but the molecular mechanisms of decidual impairment are still not fully understood. Thus, this study aimed to identify novel key genes potentially involved in RM and explore their roles played in endometrial decidualization.
Methods: Initially, a combinative analysis of decidual and mid-secretory endometrial transcriptomes was performed to discover hub genes involved in the etiology of RM. And the expression levels of hub genes were evaluated in both primary decidual stromal cells (DSCs) and decidual tissues. Subsequently, the immortalized human endometrial cell line, T-HESCs, was used to investigate whether FXYD1 overexpression affects decidualization by regulating Na/K-ATPase activity.
Results: FXYD domain containing ion transport regulator 1 (FXYD1) was identified as a hub gene in the pathogenesis of RM through various bioinformatic methods. Abnormally increased FXYD1 expression was observed in DSCs and decidual tissues from RM patients compared to that of the normal group. Furthermore, in vitro decidualization was obviously inhibited by the overexpression of FXYD1. Additionally, Na/K-ATPase activity was significantly elevated during decidualization, whereas overexpression of FXYD1 reduced Na/K-ATPase activity. Bufalin, a Na/K-ATPase inhibitor, showed an effectively inhibitory effect on decidualization.
Conclusions: Collectively, FXYD1 was discovered as a hub gene associated with RM, and its expression levels in RM patients were significantly upregulated. Increased FXYD1 expression might lead to decidualization defects by reducing Na/K-ATPase activity, of which presented a novel prospective treatment target for RM.
Keywords: Decidualization; FXYD; Hub genes; Na/K-ATPase; Recurrent miscarriage.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Ethics approval: This study involving human was approved by the Medical Ethics Committees of The Second Hospital of Tianjin Medical University (KY2017K002) and the Shanghai Institute for Biomedical and Pharmaceutical Technologies (PJ2018-06). Informed consent: Written informed consent was obtained from all participants. Conflict of interest: The authors declare no competing interests.
References
-
- Dimitriadis E, Menkhorst E, Saito S, et al. Recurrent pregnancy loss [J]. Nat Rev Dis Primers. 2020;6(1):98. 10.1038/s41572-020-00228-z. - PubMed
-
- Rai R, Regan L. Recurrent miscarriage [J]. Lancet. 2006;368(9535):601–11. 10.1016/s0140-6736(06)69204-0. - PubMed
-
- Zhang J, Liu X, Rao L, et al. Adverse obstetric and perinatal outcomes of patients with history of recurrent miscarriage: a retrospective cohort study [J]. Fertil Steril. 2023;120(3):626–34. 10.1016/j.fertnstert.2023.04.028. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
